Meet Genomadix™

Genomadix has developed the Cube, the world’s first real-time PCR point of need platform for precision medicine testing and other applications.

  • Genomadix produces molecular tests for precision medicine genotyping and environmental/water safety testing.
  • Genomadix commercializes the Cube CYP2C19 Genotyping Test, the world’s fastest and easiest FDA-cleared CYP2C19 genotyping test, which can be used to support dual antiplatelet therapy decisions for stroke and cardiology patients.
  • The Genomadix Cube is a point of care open platform, and is available for partnering with assay developers, clinical labs, laboratory service providers, and others.
  • Genomadix’s technology for the cube includes over 3 million hours of research and development, 11 patents and 30+ peer-reviewed scientific publications.

Management

Genomadix leadership team is comprised of visionary founders and seasoned professionals with decades of experience across diverse fields such as, life sciences, in vitro diagnostics, and high-tech. Together, they’ve achieved successful exits, launched innovative products, and spearheaded effective commercialization. Their combined expertise in business development, strategic planning, and international markets positions Genomadix for tremendous growth.

Hollie Huff

Hollie Huff, PhD

Chief Executive Officer (CEO)

Read More +
Jeremy Bridge-Cook

Jeremy Bridge-Cook, PhD

Chief Scientific and Marketing Officer (CSMO)

Read More +
Bern Johnson

Bern Johnson

Chief Operating Officer (COO)

Read More +
Adam Kuehl

Adam Kuehl

Chief Financial Officer (CFO)

Read More +
Genomadix Patrick Mallon

Patrick Mallon

Exec Chairman

Read More +
Genomadix Joshua Van Wezel

Joshua van Wezel

Head of Sales

Read More +

Careers

Looking to join our growing team? Learn more about what it’s like to work at Genomadix and our current openings.
Join Our Team

Ready to start working with the
Genomadix Cube?

Contact Us
Genomadix Logo

Genomadix

340 Legget Dr, Suite 180
Kanata, ON K2K 1Y6

+1 888 810 7788

Decision Diagnostics

About

Resources

Legal

© 2024 Genomadix, the Genomadix logo and all product names are the property of Genomadix or its licensors. All rights reserved. 

X-twitter Linkedin Bluesky Streamline Icon: https://streamlinehq.comBluesky

External social links open to a new page or tab.

Scroll to Top

Hollie Huff, PhD

Chief Executive Officer (CEO)

Hollie Huff is a seasoned healthcare executive and strategic leader with more than two decades of experience driving innovation, growth, and transformation across the global diagnostics and medical technology landscape. With a PhD in Analytical Chemistry and a career spanning startups to Fortune 100 companies, she brings a rare blend of scientific depth, business acumen, and deal-making expertise.

Prior to joining Genomadix as CEO, Hollie served as Head of Strategy, Corporate & Business Development at QuidelOrtho, where she built enterprise-wide governance frameworks for M&A and strategic partnerships, delivering disciplined growth aligned with corporate priorities. Prior to that, she was Senior Vice President of Strategy & Portfolio Management at Siemens Healthineers, where she led inorganic and organic innovation roadmaps, stood up a highly profitable COVID-19 antigen business, and oversaw global partnerships and acquisitions.

Her earlier roles include Vice President of Corporate Development at Abbott Laboratories and Alere, where she played a pivotal role in the $7.8B Abbott-Alere merger, managing regulatory clearances, asset divestitures, and integration strategy. Hollie began her career in R&D, holding leadership roles at Inverness Medical Innovations and Ischemia Technologies, where she was the inventor and patent holder of the IMA test for cardiac ischemia.

Throughout her career, Hollie has been recognized for her ability to translate complex science into strategic opportunity, build high-performing teams, and negotiate transformative deals that shape the future of diagnostics. She is passionate about advancing healthcare through innovation, collaboration, and bold thinking.

Jeremy bridge-Cook, PhD

Chief Scientific and Marketing Officer (CSMO)

Dr. Bridge-Cook has over 20 years of experience in various executive roles in the in vitro diagnostics industry. Prior to Genomadix, he was President & CEO of Rna Diagnostics Inc., a cancer diagnostic company based in Toronto, Canada. Prior to this position, Dr. Bridge-Cook held various executive positions at Luminex Corporation and Tm Bioscience (acquired by Luminex in 2007) for 16 years in positions of increasing responsibility. Dr. Bridge-Cook was VP of Business Development, VP Sales & Marketing and Senior VP Corporate Development at Tm Bioscience, and most recently served as Senior VP of Research & Development at Luminex Corp. While running R&D for Luminex Corp., Dr. Bridge-Cook led teams that developed the first FDA-cleared respiratory viral panel and the first FDA-cleared gastrointestinal pathogen panel, as well as developing and launching the ARIES system and several other instrument and assay launches. Prior to working at Luminex/Tm, Dr. Bridge-Cook worked as an Investment Manager at MDS Capital Corp., a venture capital company focused on Life Science investments. Dr. Bridge-Cook received his B.Sc. from McMaster University and Ph.D. in Immunology from the University of Toronto.

Bern Johnson

Chief Operating officer (COO)

Bern joined Genomadix in 2020 and is responsible for Manufacturing, Research & Development, Quality, Regulatory, Supply Chain and Logistics. Bern has more than 20 years of experience in leading operations and manufacturing for both start-ups and established companies. Prior to Genomadix, he was Vice President of Operations for eSight Eyewear, a medical device company in the low-vision assistive technology industry. Prior to this position, Bern held various senior level operations roles at BTI Systems, March Networks, Tropic Networks & Alcatel-Lucent.


Bern received a Diploma in Electronic Engineering Technology specializing in Communications from the College of the North Atlantic and a Certification in Production and Inventory Management (CPIM) from the American Production and Inventory Control Society (APICS).

Adam Kuehl

Chief Financial Officer (CFO)

Adam Kuehl is a seasoned financial executive and strategic advisor with over two decades of experience in corporate finance, mergers and acquisitions, operational leadership, and compliance. Known for his dynamic and versatile approach, Adam has consistently delivered transformative results for organizations across technology, manufacturing, and professional services sectors.  Previously, Adam served as Chief Financial Officer at Zivaro, Inc. (now Trace3 Government, LLC), where he drove significant EBITDA growth and led the company through a successful sale to Trace3, a private equity-backed platform. His expertise spans valuations, due diligence, integrations, and financial planning for large-scale transactions. Adam began his career in public accounting with BKD, LLP and EKS&H, gaining deep audit and compliance experience.

Adam holds a Bachelor’s degree in Business Administration – Accounting from the University of Iowa and earned his CPA certification in 2007.

Patrick Mallon

Exec Chairman

 

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Mauris vulputate quam non arcu viverra, at consectetur mi vestibulum. Nam lacinia velit sit amet sem rutrum, vel elementum lacus iaculis. Fusce quis auctor velit. Maecenas gravida enim sit amet sem aliquet, ut ullamcorper libero mattis. Etiam sodales pharetra augue, accumsan scelerisque turpis dignissim vel. Maecenas fermentum laoreet varius. Vestibulum non aliquam ligula. Sed metus mi, lobortis in velit semper, euismod mollis diam. Maecenas malesuada tincidunt lorem sit amet pharetra. Nunc tincidunt lacus id eros facilisis mollis. Proin mattis lobortis hendrerit. Maecenas blandit scelerisque felis at eleifend. Donec a tempus libero. Maecenas mollis nulla nisi, at iaculis turpis cursus vitae.

Joshua van Wezel

Head of Sales

 

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Mauris vulputate quam non arcu viverra, at consectetur mi vestibulum. Nam lacinia velit sit amet sem rutrum, vel elementum lacus iaculis. Fusce quis auctor velit. Maecenas gravida enim sit amet sem aliquet, ut ullamcorper libero mattis. Etiam sodales pharetra augue, accumsan scelerisque turpis dignissim vel. Maecenas fermentum laoreet varius. Vestibulum non aliquam ligula. Sed metus mi, lobortis in velit semper, euismod mollis diam. Maecenas malesuada tincidunt lorem sit amet pharetra. Nunc tincidunt lacus id eros facilisis mollis. Proin mattis lobortis hendrerit. Maecenas blandit scelerisque felis at eleifend. Donec a tempus libero. Maecenas mollis nulla nisi, at iaculis turpis cursus vitae.